Shire Pharmaceuticals Ireland Limited Takeda GmbH Takeda Pharmaceuticals International AG Ireland Branch

Poland

All drugs from this manufacturer

  • ELVANSE

    The medicine is used as part of the comprehensive treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 18 years (if previous treatment with methylphenidate has not helped) and in adults who have had ADHD since childhood.

    Dosage form: capsules, hard

    Active substance Dosage
    lisdexamfetamine mesylate 30 mg

    ATC: N06BA12

  • ELVANSE

    The medicine is used as part of the comprehensive treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 18 years (if methylphenidate has not been effective) and in adults who have had ADHD since childhood.

    Dosage form: capsules, hard

    Active substance Dosage
    lisdexamfetamine mesylate 50 mg

    ATC: N06BA12

  • ELVANSE

    The medicine is used as part of the comprehensive treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6–18 years (if methylphenidate has not been effective) and in adults who have had ADHD since childhood. It helps to facilitate concentration and reduce hyperactivity.

    Dosage form: capsules, hard

    Active substance Dosage
    lisdexamfetamine mesylate 70 mg

    ATC: N06BA12

  • ELVANSE

    The medicine is used as part of the comprehensive treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6–18 years (if methylphenidate has not been effective) and in adults who have had ADHD since childhood.

    Dosage form: capsules, hard

    Active substance Dosage
    lisdexamfetamine mesylate 20 mg

    ATC: N06BA12

  • ELVANSE

    The medicine is used as part of the comprehensive treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 18 years (if methylphenidate has not been effective) and in adults who have had ADHD since childhood.

    Dosage form: capsules, hard

    Active substance Dosage
    lisdexamfetamine mesylate 40 mg

    ATC: N06BA12

  • ELVANSE

    The medicine is used as part of the comprehensive treatment of attention deficit hyperactivity disorder (ADHD). It helps to facilitate attention, improve concentration, and reduce hyperactivity.

    Dosage form: capsules, hard

    Active substance Dosage
    lisdexamfetamine mesylate 60 mg

    ATC: N06BA12